If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...

Incomplete lupus erythematosus (ILE) remains one of the more difficult areas we face in rheumatology. Patients may present with a positive antinuclear antibody and a few symptoms of systemic lupus ...

ABSTRACT: Introduction: Hematologic abnormalities affect many patients with systemic lupus erythematosus (SLE). Despite their clinical relevance, standardized treatment guidelines remain limited, and ...

aRheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain Antiphospholipid syndrome is a rare ...

Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, induces potent B-cell depletion and is approved for the treatment of active lupus nephritis. Its efficacy and safety in patients ...

Credit: Getty Images Understanding the underlying mechanisms and immunological dysfunction of SLE is essential to appreciate its diverse clinical manifestations and guide effective diagnosis and ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

In reflecting on the American College of Rheumatology conference, Dr Maureen McMahon describes the impact of new guidelines on early diagnosis in systemic lupus erythematosus (SLE) and lupus nephritis ...

Belimumab may reduce the risk for all-cause mortality compared with oral immunosuppressants among patients with nonrenal systemic lupus erythematosus. Belimumab use is associated with a reduced risk ...

New results from a study of a drug called Gazyva (obinutuzumab) showed that it significantly reduced disease activity in adults with systemic lupus erythematosus (SLE). The drug was developed by ...